Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor Marian IwamotoEvan J. FriedmanJohn A. Wagner Review Article 03 July 2013 Pages: 493 - 508
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids Susan SunJoseph SchallerBrett Duersch Original Article 17 July 2013 Pages: 509 - 513
Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel D. SémiondS. S. SidhuP. Vrignaud Original Article 03 July 2013 Pages: 515 - 528
Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival Cassio Cardoso-FilhoLuis Otavio SarianMaria Salete Costa Gurgel Original Article 11 July 2013 Pages: 529 - 535
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer Dana E. RathkopfJoel PicusGeorge Wilding Original Article 03 July 2013 Pages: 537 - 544
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer Krishna RaoSini KalapurakalK. Thomas Robbins Original Article 25 July 2013 Pages: 545 - 552
Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells Salaheldin S. HamedRobert M. StraubingerWilliam J. Jusko Original Article 09 July 2013 Pages: 553 - 563
Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study Changhoon YooMi Ra YunSung-Bae Kim Original Article 11 July 2013 Pages: 565 - 575
Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors Kazunori HondaNoboru YamamotoTomohide Tamura Original Article 17 July 2013 Pages: 577 - 584
Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor Andrea S. FungMan YuIan F. Tannock Original Article 14 July 2013 Pages: 585 - 595
The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor Michele VisentinErsin Selcuk UnalI. David Goldman Original Article 24 July 2013 Pages: 597 - 606
A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients Meagan J. BemerMohamed SorrorJeannine S. McCune Original Article 02 August 2013 Pages: 607 - 618
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours Takashi SetoTaito EsakiXiaojin Shi Original Article 28 July 2013 Pages: 619 - 627
CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702) Yoshinari MochizukiNorifumi OhashiYasuhiro Kodera Original Article 24 July 2013 Pages: 629 - 635
A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer Yee ChaoChen-Yi WuChung-Pin Li Original Article 03 August 2013 Pages: 637 - 642
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer Toshihiko DoiKei MuroAtsushi Ohtsu Original Article Open access 07 August 2013 Pages: 643 - 652
Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer Taejong SongMin Kyu KimDuk Soo Bae Original Article 03 August 2013 Pages: 653 - 660
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes Jill M. KolesarAnne M. TraynorWilliam R. Schelman Original Article 01 August 2013 Pages: 661 - 667
The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer Beatrice Mohelnikova-DuchonovaVeronika BrynychovaPavel Soucek Original Article 11 August 2013 Pages: 669 - 682
Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing Ana Podolski-RenićMilka JadraninMilica Pešić Original Article 10 August 2013 Pages: 683 - 697
Effects of β-lapachone, a new anticancer candidate, on cytochrome P450-mediated drug metabolism In Sook KimYun KimHye Hyun Yoo Short Communication 23 July 2013 Pages: 699 - 702
The small-molecule TNF-α inhibitor, UTL-5g, delays deaths and increases survival rates for mice treated with high doses of cisplatin Jiajiu ShawJoseph MediaFredrick Valeriote Short Communication 24 July 2013 Pages: 703 - 707
Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia Neta GoldschmidtAlexander GuralMoshe E. Gatt Short Communication 02 August 2013 Pages: 709 - 713